The GSE135222 dataset of NSCLC patients undergoing anti-PD-1 therapy was examined to more thoroughly assess this, and we discovered that those with a high-risk score had shorter survival times (p=0.0027) (Figure 10A). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.